{"url_path":"/fda/drug/recalls/D-0732-2026","section_key":"summary","section_title":"DRUG Recall: JB Chemicals and Pharmaceuticals Ltd — Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.","topic":"fda","document":{"doc_type":"drug-recall","doc_date":"2026-06-24","source_url":"https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0732-2026%22","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"JB Chemicals and Pharmaceuticals Ltd"},"word_count":110,"has_tables":false,"body_markdown":"# FDA DRUG Recall: D-0732-2026\n\n**Recalling firm:** JB Chemicals and Pharmaceuticals Ltd\n**Classification:** Class I\n**Status:** Ongoing\n**Type:** Voluntary: Firm initiated\n**Initiated:** 2026-06-24\n**Report date:** 2026-07-29\n\n## Product\nCetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.\n\n## Reason\nCross Contamination with Other Products: Customer complaints for appearance of  discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.\n\n## Affected lots\nLots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT\n\n## Distribution\nNationwide in the USA"}